User login
Key clinical point: Erenumab treatment significantly improved the number of headache days in patients with onabotulinumtoxinA-resistant chronic migraine.
Major finding: Erenumab significantly reduced the number of headache days that limited activities of daily living at 3 months (−6.4 days), 6 months (−6.8 days), and 9 months (−6.5 days; P for all = .001).
Study details: Real-world outcomes were assessed in 98 patients with difficult-to-control chronic migraine and a prior unsatisfactory response to onabotulinumtoxinA.
Disclosures: This study did not receive any funding. Erenumab was provided free of charge by Novartis. S Weatherby attended conferences/received speakers fees from Novartis.
Source:Talbot J et al. J Headache Pain. 2021 Jan 9. doi: 10.1186/s10194-020-01214-2.
Key clinical point: Erenumab treatment significantly improved the number of headache days in patients with onabotulinumtoxinA-resistant chronic migraine.
Major finding: Erenumab significantly reduced the number of headache days that limited activities of daily living at 3 months (−6.4 days), 6 months (−6.8 days), and 9 months (−6.5 days; P for all = .001).
Study details: Real-world outcomes were assessed in 98 patients with difficult-to-control chronic migraine and a prior unsatisfactory response to onabotulinumtoxinA.
Disclosures: This study did not receive any funding. Erenumab was provided free of charge by Novartis. S Weatherby attended conferences/received speakers fees from Novartis.
Source:Talbot J et al. J Headache Pain. 2021 Jan 9. doi: 10.1186/s10194-020-01214-2.
Key clinical point: Erenumab treatment significantly improved the number of headache days in patients with onabotulinumtoxinA-resistant chronic migraine.
Major finding: Erenumab significantly reduced the number of headache days that limited activities of daily living at 3 months (−6.4 days), 6 months (−6.8 days), and 9 months (−6.5 days; P for all = .001).
Study details: Real-world outcomes were assessed in 98 patients with difficult-to-control chronic migraine and a prior unsatisfactory response to onabotulinumtoxinA.
Disclosures: This study did not receive any funding. Erenumab was provided free of charge by Novartis. S Weatherby attended conferences/received speakers fees from Novartis.
Source:Talbot J et al. J Headache Pain. 2021 Jan 9. doi: 10.1186/s10194-020-01214-2.